Early buyers will receive 10% customization on this report.
In this report, the global epigenetics market is segmented based on product, research areas, and geography. High prevalence of cancer, increasing intensity of research activities, increasing funding, increasing application of non-oncology diseases and growing partnership between academic and biotechnology & pharmaceutical companies are the major drivers for epigenetics market.
The major players in the global epigenetics market are Abcam plc. (U.K), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherland), Merck & Co. (U.S.), New England Biolabs, Inc. (U.S.), Sigma-Aldrich Corporation (U.S.), Thermo Fisher Scientific, Inc., (U.S.), Active Motif (U.S.), Diagenode, Inc. (Belgium) and Zymo Research Corporation (U.S.).
The global epigenetics market is growing at a CAGR of 13.64% between 2015 and 2020. There is a high degree of fragmentation in this market. An analysis of the market developments between 2011 and 2015 reveals that new product launches was the most important growth strategy for market players in this period.
This strategy was adopted by most of the players in this market— Abcam plc. (U.K), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherland) and Merck & Co. (U.S.), New England Biolabs, Inc. (U.S.), Sigma-Aldrich Corporation (U.S.), Thermo Fisher Scientific, Inc., (U.S.), Diagenode, Inc. (Belgium) and Zymo Research Corporation (U.S.).
The other important growth strategies adopted were acquisition, agreement, alliance, collaboration & partnership, expansion, and other developments. Other developments include certification, divestiture, grant, market initiative, patent, product enhancement, and regulatory approval.
These strategies were adopted by players for expanding their existing product portfolios and widening their geographic presence. Abcam plc. (U.K), Illumina, Inc. (U.S.), New England Biolabs, Inc. (U.S.), QIAGEN N.V. (Netherland), and Thermo Fisher Scientific, Inc. (U.S.) are some players that adopted these strategies.
About MarketsandMarkets:
MarketsandMarkets is the largest market research firm worldwide in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.
M&M’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
